Document is current
Any future updates will be listed below
-
Authors
da Silva, Edaise M. https://orcid.org/0000-0003-3281-7333
Selenica, Pier
Vahdatinia, Mahsa https://orcid.org/0000-0002-9424-537X
Pareja, Fresia https://orcid.org/0000-0003-3748-8049
Da Cruz Paula, Arnaud
Ferrando, Lorenzo https://orcid.org/0000-0002-4025-7930
Gazzo, Andrea M.
Dopeso, Higinio https://orcid.org/0000-0003-0060-1861
Ross, Dara S.
Bakhteri, Ariya
Riaz, Nadeem https://orcid.org/0000-0001-9873-5862
Chandarlapaty, Sarat https://orcid.org/0000-0003-4532-8053
Razavi, Pedram https://orcid.org/0000-0003-4236-0576
Norton, Larry
Wen, Hannah Y.
Brogi, Edi https://orcid.org/0000-0003-4737-8468
Weigelt, Britta https://orcid.org/0000-0001-9927-1270
Zhang, Hong
Reis-Filho, Jorge S. https://orcid.org/0000-0003-2969-3173
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30CA008748, P50 CA247749 01, K12 CA184746, P50 CA247749 01, P50 CA247749 01)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Breast Cancer Research Foundation
U.S. Department of Health & Human Services | NIH | National Cancer Institute
- License Information
-
More Information
Article History
Received: 6 October 2020
Accepted: 15 March 2021
First Online: 16 April 2021
Competing interests
: S.C. has received personal/consultancy fees from Lilly, Novartis, and Paige.AI. S.C. also reports research funds directed to MSK from Sanofi, Novartis, Daiichi-Sankyo, and Lilly, outside the scope of this study. H.Y.W. performed consulting/advisory services for Merck at one teleconference. H.Z. reports consultancy fee from Roche/Genentech, outside the scope of the submitted work. J.S.R.-F. reports receiving personal/consultancy fees from Goldman Sachs and REPARE Therapeutics, membership of the scientific advisory boards of VolitionRx, REPARE Therapeutics and Paige.AI, membership of the Board of Directors of Grupo Oncoclinicas, and ad hoc membership of the scientific advisory boards of Roche Tissue Diagnostics, Ventana Medical Systems, Novartis, Genentech and InVicro, outside the scope of this study. J.S.R.-F. and L.N. are editors with the journal. The remaining authors declare no competing interests.
